Cochlear FY26 earnings preview

Cochlear overview 

Cochlear (ASX: COH) is the global leader in implantable hearing solutions. The company designs, manufactures and supplies cochlear implants, bone conduction systems and related sound processors and services, helping people with moderate-to-profound hearing loss reconnect with the world of sound.

When will Cochlear report its latest earnings?

Cochlear is scheduled to release its full-year results for the 12 months ending 30 June 2026 on Tuesday, 18 August 2026.

The backdrop

In its half-year 2026 (HY26) results (released 13 February), Cochlear delivered a softer-than-expected performance as the company navigated the early stages of its Nucleus Nexa System rollout. The Nexa is the world's first and only smart cochlear implant system with upgradeable firmware. 

Key numbers:

• Sales revenue $1,176 million, up 1% (down 2% in constant currency)
• Underlying net profit $195 million, down 9%
• Statutory net profit $161.5 million, down 21%
• Interim dividend held steady at $2.15 per share
• Gross margin compressed 2 percentage points to 73%

While implant units rose 6%, revenue lagged due to a higher mix of lower-priced emerging-market sales. The bigger issue for investors was the slower-than-anticipated product registration and contract renewal process for the new Nexa System, particularly where price increases were being sought. This delayed the expected uplift in developed markets and left first-half growth in low single digits there.

Chief executive officer (CEO) Dig Howitt noted that the first half was heavily focused on the Nexa launch and acknowledged that the contracting process 'took longer than anticipated'. He remained confident the company would get on top of the delays and deliver a stronger second half (H2) once the system was more broadly available.

Management guided underlying net profit to the lower end of the previous $435 – $460 million range and flagged that a stronger Australian dollar could shave a further ~$30 million off the result if rates stayed elevated.

The market reaction was sharp. Cochlear shares finished the day 18.90% lower at $199.22. Investors were clearly disappointed by the combination of muted top-line growth, the profit decline, the delayed Nexa contribution, and the more cautious full-year outlook after what had been a period of high expectations for the new product cycle. 

Cochlear HY26 results

Highlights from the most recent update

The picture deteriorated further in April. On 22 April, Cochlear issued a trading update that shocked the market. Soft trading conditions in developed markets since January (flat revenue in constant currency for the quarter), hospital capacity constraints in Europe, weaker referrals from the hearing-aid channel, and heightened uncertainty in the Middle East due to the ongoing conflict forced a sharp cut to guidance.

A significant additional headwind in the United States (US) was the impact of cuts to Medicaid coverage for hearing implants legislated under President Trump's One Big Beautiful Bill Act (OBBB). These changes restricted reimbursement and weighed heavily on Cochlear's American business. Management also specifically called out the sharp decline in US consumer sentiment (University of Michigan Index of Consumer Sentiment) as a key uncertainty for implant demand – important given that the Americas represent roughly 50% of group revenue.

Underlying net profit guidance for FY26 was slashed by around 31% at the midpoint, from the previous $435 – $460 million range to $290 – $330 million. Management also flagged potential receivables provisions (up to ~$10 million), lower gross margins from reduced production volumes (~$20 million impact), costs from accelerating a cost-base reshape ($18 – $25 million), and a stronger Australian dollar (~$25 million after-tax headwind).

CEO Dig Howitt said: 'Addressing hearing loss in adults and seniors continues to be treated as a discretionary intervention, highlighting the importance of our strategy to medicalise hearing loss so that treatment is recognised as an important health priority… We remain confident of our market leadership.'

The market reaction was brutal. Cochlear shares dived 40.71% to finish at $99.58 – levels last seen a decade earlier – in the biggest single-day fall since its 1995 listing, wiping billions off its market value. 

Trading update and revised net profit guidance

What to expect from Cochlear earnings

The market will be focused on whether Cochlear lands inside (or at the lower end of) its revised $290 million – $330 million underlying net profit guidance range after the heavy April downgrade.

Key things to watch:

• 2H sales growth – guidance is for +2–6% in constant currency. Consensus is currently leaning toward the bottom end of that range, reflecting ongoing softness in developed-market cochlear implant volumes.
• US demand and consumer sentiment – the Americas account for roughly half of group revenue. US consumer sentiment hit all-time lows earlier in the year and only partially recovered. Any commentary on whether this is still weighing on adult and senior implant decisions will be closely scrutinised.
• Services and Acoustics contribution – these segments held up better in the third quarter (+13% and +11% CC respectively). Investors will want confirmation that the installed-base upgrade cycle and Osia/Baha momentum remained solid in the fourth quarter. 
• Cost-base reshape and one-offs – details on the $18–25 million restructuring costs and any Middle East receivables provisions. 
• Nexa System progress – market-share commentary and whether the price premium is sticking. 
• Early FY27 outlook – management’s tone on the pace of any recovery, surgical backlogs, and whether a catch-up in delayed procedures is realistic in the near term.

A clean result at or above the low end of guidance combined with constructive FY27 commentary would be well received. Anything that suggests further pressure on developed-market volumes would likely weigh on the shares.

Key financial - Summary

• Sales revenue: ~$2.32 billion (down ~1% on FY25’s $2.34 billion)
• Underlying / Net profit: ~$304 million (down ~22% on FY25), sitting comfortably inside the $290–$330 million guidance range and slightly below the midpoint
• Earnings per share (EPS): ~$4.73 (down ~21%)
• Dividend per share: ~$3.42 (down ~21% from $4.30 in FY25)

Cochlear underlying net profit

Cochlear technical analysis

From its July 2024 peak of $350.31, Cochlear's share price fell approximately 75% to the April 2026 low of $88.74. The decline accelerated sharply through February, March and April of this year as the market digested the dual earnings shocks – the softer-than-expected HY26 result and the subsequent major guidance cut.

The rebound from the $88.74 low has so far been tentative and corrective in nature. Given the sheer scale of the preceding decline, the potential for this recovery to extend further remains significant. The 38.2% Fibonacci retracement of the entire $350.31 – $88.74 fall sits near $188.70, while the 50% retracement comes in around $219.50.

In the near term, the shares will need to clear resistance in the $150 – $160 zone (created by the large gap lower in April) to suggest the corrective rally is gaining real traction. A sustained break above that area would open the way toward the higher Fibonacci targets.

Until then, the broader technical picture remains one of a market still repairing the heavy damage from the 2026 sell-off.

Cochlear weekly chart

• _{Source: TradingView. The figures stated are as of 12 August 2026. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation.}